SEC Form 4 · accession 0001209191-19-008592

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, CRO

Period of report

Feb 6, 2019

Accepted (ET)

Feb 8, 2019 · 4:51 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 6, 2019	A	17,298	$0.00	A	55,335	D
Common Stock^F2	Feb 6, 2019	A	10,126	$0.00	A	65,461	D
Common Stock^F3	Feb 6, 2019	A	9,799	$0.00	A	75,260	D
Common Stock	holding	—	—		—	12,215	I	Held in Trust
Common Stock	holding	—	—		—	882	I	401(k)

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$187.53	Feb 6, 2019	A	25,026	A	—	Feb 5, 2029	Common Stock	25,026	25,026	D

F1Represents earned performance shares with respect to a performance stock unit award granted on 2/2/2016 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019 and the shares will vest on 2/10/2019.
F2Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019.
F3Restricted stock unit award that vests in installments beginning on 2/24/2020.
F4The option vests in 16 quarterly installments from 2/6/2019.